Who are Low dose erythropoietin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aranesp, Epogen, Epogen, Erythropoietin carried on chitosan carrier, continuation (darbepoetinum), recomon (Epoetin Beta).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-erythropoietin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Low dose erythropoietin — Competitive Intelligence Brief

Low dose erythropoietin (Low dose erythropoietin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent. Area: Hematology.

marketed Erythropoiesis-stimulating agent Erythropoietin receptor (EPOR) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Low dose erythropoietin (Low dose erythropoietin) — VA Office of Research and Development. Low-dose erythropoietin stimulates erythroid progenitor cells in the bone marrow to increase red blood cell production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Low dose erythropoietin TARGET	Low dose erythropoietin	VA Office of Research and Development	marketed	Erythropoiesis-stimulating agent	Erythropoietin receptor (EPOR)
Aranesp	DARBEPOETIN ALFA	Amgen	marketed	Erythropoiesis-stimulating Agent [EPC]	Erythropoietin receptor	2001-01-01
Epogen	EPOETIN ALFA	Amgen	marketed	Erythropoiesis-stimulating Agent	Erythropoietin receptor	1989-01-01
Epogen	Epoetin Alfa-Epbx	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor	1989-01-01
Erythropoietin carried on chitosan carrier	Erythropoietin carried on chitosan carrier	Ain Shams University	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
continuation (darbepoetinum)	continuation (darbepoetinum)	Anemia Working Group Romania	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
recomon (Epoetin Beta)	recomon (Epoetin Beta)	JW Pharmaceutical	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent class)

VA Office of Research and Development · 2 drugs in this class
Hoffmann-La Roche · 1 drug in this class
Hospira, now a wholly owned subsidiary of Pfizer · 1 drug in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 drug in this class
Remedor Biomed Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low dose erythropoietin — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-erythropoietin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab